Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy-Differences in Cardiotoxicity.

Saved in:
Bibliographic Details
Title: Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy-Differences in Cardiotoxicity.
Authors: Buchalska B; Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097, Warsaw, Poland., Kamińska K; Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097, Warsaw, Poland. kkaminska@wum.edu.pl., Kowara M; Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097, Warsaw, Poland., Sobiborowicz-Sadowska A; Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097, Warsaw, Poland., Cudnoch-Jędrzejewska A; Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097, Warsaw, Poland.
Source: Cardiovascular toxicology [Cardiovasc Toxicol] 2025 Feb; Vol. 25 (2), pp. 248-268. Date of Electronic Publication: 2025 Jan 15.
Publication Type: Journal Article; Review; Comparative Study
Journal Info: Publisher: Humana Press Country of Publication: United States NLM ID: 101135818 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0259 (Electronic) Linking ISSN: 15307905 NLM ISO Abbreviation: Cardiovasc Toxicol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1559-0259
DOI:10.1007/s12012-024-09952-4